Phase 2 Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials
24 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 24 trials
Recruiting
Phase 2
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)CD5 Positive
Sun Yat-sen University60 enrolled1 locationNCT07494565
Recruiting
Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center42 enrolled8 locationsNCT06765317
Recruiting
Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+6 more
Miltenyi Biomedicine GmbH315 enrolled32 locationsNCT04792489
Recruiting
Phase 1Phase 2
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)ALL (Acute B-Lymphoblastic Leukemia)+4 more
Curocell Inc.91 enrolled2 locationsNCT04836507
Recruiting
Phase 2
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University35 enrolled1 locationNCT07608978
Recruiting
Phase 2
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Liling Zhang40 enrolled1 locationNCT06867536
Recruiting
Phase 2
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Diffuse Large B-Cell Lymphoma (DLBCL)
University Health Network, Toronto40 enrolled3 locationsNCT06050694
Recruiting
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 2
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University35 enrolled1 locationNCT07499271
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 2
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD50 enrolled1 locationNCT07493148
Recruiting
Phase 1Phase 2
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Relapsed Large B-cell Lymphoma+3 more
TICAROS Co., Ltd.98 enrolled1 locationNCT07473167
Recruiting
Phase 2
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital58 enrolled1 locationNCT07397832
Recruiting
Phase 2
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Beijing Tongren Hospital50 enrolled1 locationNCT07371923
Recruiting
Phase 2
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Primary CNS Lymphoma (PCNSL)
Hyungwoo Cho12 enrolled1 locationNCT07062627
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2Phase 3
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University80 enrolled1 locationNCT07084662
Recruiting
Phase 2
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Diffuse Large B-Cell Lymphoma (DLBCL)
Danielle Wallace40 enrolled1 locationNCT06828991
Recruiting
Phase 2
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07078500
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936